Ligand Pharmaceuticals | LGND - Trade Creditors


Ligand Pharmaceuticals reported $37.11M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Agenus USD 71.08M 11.9M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
Anika Therapeutics USD 6.34M 298K Mar/2026
Arrowhead Research USD 30.75M 2.19M Mar/2026
Baxter International USD 1.09B 87M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Enviri Corporation USD 257.33M 17.68M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Glaxosmithkline GBP 20.72B 346.14M Dec/2025
Heron Therapeutics USD 8.97M 24K Mar/2026
Insmed USD 73.38M 6.53M Mar/2026
Intrexon USD 4.85M 3.12M Jun/2024
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Karyopharm Therapeutics USD 4M 1.39M Dec/2025
Ligand Pharmaceuticals USD 37.11M 33.87M Mar/2026
MacroGenics USD 4.29M 500K Mar/2026
Merck USD 3.86B 541M Mar/2026
Pacira USD 14.01M 1.14M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Veracyte USD 6.91M 2.32M Mar/2026